Results 1 to 10 of about 1,512,475 (325)
Background Cutaneous reactions after messenger RNA (mRNA)-based COVID-19 vaccines have been reported but are not well characterized. Objective To evaluate the morphology and timing of cutaneous reactions after mRNA COVID-19 vaccines.
Devon E Mcmahon +2 more
exaly +2 more sources
A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson
The novel coronavirus outbreak was declared a pandemic in March 2020. We are reviewing the COVID-19 vaccines authorized for use in the United States by discussing the mechanisms of action, administration, side effects, and efficacy of vaccines developed ...
Rikin Patel +4 more
doaj +2 more sources
La crisis no moderna de la universidad moderna [PDF]
[La crisis no moderna de la universidad moderna]William Thayer.Editorial Cuarto Propio,Santiago, 1996,239 ...
Oyarzún, Pablo
core +4 more sources
“COVID arm”: A reaction to the Moderna vaccine
INTRODUCTION TheModerna mRNA-1273 vaccine was authorized by the Food and Drug Administration for emergency use during the ongoing COVID-19 pandemic in December 2020.
N. Wei +4 more
exaly +2 more sources
Summary Background Vaccination against COVID-19 is the cornerstone to control and mitigate the ongoing pandemic. Thrombotic adverse events linked to Moderna, Pfizer and the Oxford-AstraZeneca vaccine have been documented and described as extremely rare ...
Mansour Tobaiqy +2 more
exaly +2 more sources
IgG4 Neutralization and Sustained Total IgG Fc-Effector Functions Following Repeated SARS-CoV-2 Vaccination with mRNA-1273 [PDF]
Introduction Detailed characterization of the antibody profile induced by SARS-CoV-2 mRNA vaccines has shown that repeat dosing boosts all immunoglobulin G (IgG) subclasses, with a notable emergence of antigen-specific IgG4 antibodies.
Paulina Kaplonek +10 more
doaj +2 more sources
Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report
Background In December 2020, Moderna released the mRNA-1273 vaccine. The most common side effects are headache, muscle pain, redness, swelling, and tenderness at the injection site.
Joyce Kong +2 more
exaly +2 more sources
Potent and dose-sparing next-generation SARS-CoV-2 vaccine, mRNA-1283, induces polyfunctional and durable T cell immunity [PDF]
Cell-mediated immunity contributes to durable protection against severe COVID-19, particularly as antibody responses wane or viral variants partially evade neutralization.
Yamuna D. Paila +10 more
doaj +2 more sources
As of January 20, 2021, a total of 24,135,690 cases of coronavirus disease 2019 (COVID-19) and 400,306 associated deaths had been reported in the United States (https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days). On December 18, 2020,
Anonymous
semanticscholar +2 more sources
Three COVID-19 vaccines are authorized or approved for use among adults in the United States (1,2). Two 2-dose mRNA vaccines, mRNA-1273 from Moderna and BNT162b2 from Pfizer-BioNTech, received Emergency Use Authorization (EUA) by the Food and Drug ...
W. Self +157 more
semanticscholar +1 more source

